Pharmacology Flashcards
Mechanism of Penicillins.
D-Ala-D-Ala structural analog binds PBP transpeptidases and blocks cross-linking of peptidoglycan cell wall - build-up of precursors cause activation of autolytic enzymes.
Gram+:
S. pneumo
S. pyogenes
Actinomyces
Gram- cocci:
N. meningitidis
Others:
T. pallidum
PROTOTYPE PENICILLINS
Penicillin G (IV/IM) Penicillin V (PO)
May cause…
Hypersensitivity reactions
Directs Coombs+ hemolytic anemia
Resistance by…
B-lactamase (Penicillinase)
Gram+:
Listeria
Enterococcus
Gram-: E. coli Proteus Salmonella Shigella HIB H. pylori
PENICILLINASE-SENSITIVE PENICILLINS
Amoxicillin (greater oral bioavailability)
Amoxicillin-Clavulanate (Augmentin)
Ampicillin
Ampicillin-Sulbactam (Unasyn)
May cause…
Hypersensitivity reactions
Pseudomembranous colitis
Resistance by…
B-lactamase (Penicillinase)
Gram+
S. aureus (not MRSA)
PENICILLINASE-RESISTANT PENICILLINS
Bulky R group blocks binding of B-lactamase
Dicloxacillin
Nafcillin
Oxacillin
May cause…
Hypersensitivity reactions
Interstitial nephritis
Resistance by…
Altered PBP target site on MRSA
ESBL
Gram-:
Enteric rods
Pseudomonas
ANTIPSEUDOMONAL PENICILLINS
Piperacillin-Tazobactam (Zosyn)
Ticarcillin-Clavulanate (Co-Ticarclav)
May cause…
Hypersensitivity reactions
Mechanism of Cephalosporins.
D-Ala-D-Ala structural analog binds PBP transpeptidases and blocks cross-linking of peptidoglycan cell wall - Excess precursors cause activation of autolytic enzymes
More resistant to B-lactamases than Penicillins
Gram+:
Presurgical coverage of S. aureus
Cocci (staph/strep)
Gram-:
E. coli
Klebsiella
Proteus
1ST GENERATION CEPHALOSPORINS
Cefazolin
Cephalexin
May cause... Hypersensitivity reactions Autoimmune hemolytic anemia Disulfiram-like reaction Vit K deficiency Increases nephrotoxicity of Aminoglycosides
Resistance by…
Structural changes in PBP
ESBL
Gram+:
Cocci
Gram-: E. coli Klebsiella Proteus Neisseria HIB Enterobacter Serratia
2ND GENERATION CEPHALOSPORINS
Cefaclor
Cefoxitin
May cause... Hypersensitivity reactions Autoimmune hemolytic anemia Disulfiram-like reaction Vit K deficiency Increases nephrotoxicity of Aminoglycosides
Resistance by…
Structural changes in PBP
ESBL
Serious Gram- infections
3RD GENERATION CEPHALOSPORINS
Ceftriaxone (Neisseria, disseminated Lyme)
Ceftazidime (Pseudomonas)
May cause... Hypersensitivity reactions Autoimmune hemolytic anemia Disulfiram-like reaction Vit K deficiency Increases nephrotoxicity of Aminoglycosides
Resistance by…
Structural changes in PBP
ESBL
Serious Gram- infections
Increased activity against Pseudomonas
4TH GENERATION CEPHALOSPORINS
Cefepime
May cause... Hypersensitivity reactions Autoimmune hemolytic anemia Disulfiram-like reaction Vit K deficiency Increases nephrotoxicity of Aminoglycosides
Resistance by…
Structural changes in PBP
ESBL
Broad Gram- and Gram+ coverage
MRSA
Does not cover Pseudomonas.
5H GENERATION CEPHALOSPORINS
Ceftaroline
May cause... Hypersensitivity reactions Autoimmune hemolytic anemia Disulfiram-like reaction Vit K deficiency Increases nephrotoxicity of Aminoglycosides
Mechanism of Carbapenems.
D-Ala-D-Ala structural analog binds PBP transpeptidases and blocks cross-linking of peptidoglycan cell wall - build-up of precursors cause activation of autolytic enzymes
B-lactamase resistant
Life-threatening…
Gram+ cocci
Gram- rods (e.g. ESBL)
Anaerobes
CARBAPENEMS
Ertapenem
Meropenem (decreased seizure risk)
Imipenem-Cilastatin (decreased deactivation in renal tubules by dehydropeptidase I)
May cause…
GI distress
Skin rash
Seizures
Mechanism of Monobactams.
D-Ala-D-Ala structural analog binds PBP transpeptidases and blocks cross-linking of peptidoglycan cell wall - build-up of precursors cause activation of autolytic enzymes
More resistant to B-lactamases than Penicillins
Gram- rods for Penicillin-allergic patients, or those with renal insufficiency who can’t tolerate Aminoglycosides.
Note - Pseudomonal coverage
MONOBACTAMS
Aztreonam
May cause…
Occasional GI upset
Resistance by…
ESBL
Mechanism of Glycopeptides (Vancomycin, Bacitracin).
Inhibits cell wall peptidoglycan synthesis formation by binding D-ala-D-ala portion of cell wall glycoproteins - Prevents transpeptidase from making cross-links
B-lactamase resistant
Serious Gram+: MRSA (drug-resistant) S. epidermidis (biofilm producing) Enterococcus Clostridium difficile (bacteriostatic)
VANCOMYCIN
May cause... Nephrotoxicity Ototoxicity Thrombophlebitis Flushing (Red Man Syndrome) - prevent with antihistamines
Resistance by…
Amino acid modification to D-ala-D-lac
Mechanism of Aminoglycosides.
Inhibits protein synthesis by irreversible inhibition of initiation complex via binding to 30S subunit
Misreading of mRNA
Synergistic with B-lactams/Vanc - Help it enter the cell
Severe Gram- rod infections (e.g. endocaditis)
Bowel surgery
Note - Ineffective against Anaerobes
AMINOGLYCOSIDES
Amikacin Gentamycin Neomycin (bowel surgery) Streptomycin Tobramycin
May cause.. Nephrotoxicity Ototoxicity (with loop diuretic) Neuromuscular blockade Teratogen (Ototoxicity)
Resistance by…
Transferase inactivation of drug
Mutated Ribosome
Mutated Porin
Mechanism of Tetracyclines.
Inhibits protein synthesis by binding to 30S and preventing attachment of aminoacyl-tRNA.
Borrelia burgdorferi
Mycoplasma
Rickettsia/Chlamydia (intracellular accumulation)
Propionibacterium acnes
Do not take with milk (Ca), antacids (Ca, Mg) or Fe as divalent cations inhibit gut absorption
TETRACYCLINES
Tetracycline
Doxycycline (fecal elimination; renal failure patients)
Minocycline
Tigecycline (MRSA coverage)
May cause…
GI distress/Pill esophagitis
Photosensitivity
Teratogen (Teeth, Bone)
Resistance by…
Decreased uptake or increased efflux by plasmid-encoded transport pumps
Mechanism of Chloramphenicol.
Inhibits protein synthesis by blocking peptidyl transferase at 50S, preventing transfer of growing polypeptide strand to A site.
HIB meningitis
N. meningitidis
S. pneumo meningitis
Rickettsia rickettsii
Toxic but low cost
CHLORAMPHENICOL
May cause…
Dose dependent anemia
Dose independent aplastic anemia
Gray baby syndrome if premature (no UDPGT)
Resistance by…
Plasmid-encoded acetyltransferase inactivates drug
Mechanism of Clindamycin.
Inhibits protein synthesis by blocking peptide transfer at 50S subunit from A site to P site.
Anaerobes above the diaphragm:
Clostridium perfringens
Bacteroides (anaerobic lung abscess)
Gram+:
Invasive GAS pyogenes
CLINDAMYCIN
May cause…
Pseudomembranous colitis
Mechanism of Oxazolidinones.
Inhibits protein synthesis by binding to 50S subunit and preventing formation of initiation complex.
Gram+ species including MRSA and VRE.
OXAZOLIDINONES
Linezolid
May cause…
Serotonin syndrome
Bone marrow suppression/Thrombocytopenia
Peripheral neuropathy
Resistance by…
Point mutation of rRNA
Mechanism of Macrolides.
Inhibit protein synthesis by binding to 23S rRNA of 50S subunit to block translocation.
Note - Fidaxomicin inhibits the sigma subunit of RNA polymerase instead
Atypical pneumonia (Myco/Legion/Chlamy)
Chlamydia
B. pertussis
Prophylaxis for mycobacterium avium (CD4 < 50)
Strep infections in Penicillin-allergic patients
Note - Increases serum concentration of anticoagulants
Note - Using a P450 inhibitor increases blood levels
MACROLIDES
Azithromycin
Clarithromycin (P450 inhibition)
Erythromycin (P450 inhibition)
Fidaxomicin (treats c. diff)
May cause... Prolonged QT Gastrointestinal motility issues Cholestatic hepatitis Rash Eosinophilia Myopathy with Statins (metabolized by P450)
Resistance by…
Methylation of 23S rRNA-binding site
Mechanism of Sulfonamides and Dapsone.
Inhibit folate synthesis via inhibition of dihydropteroate synthase.
Gram+
Gram-
Nocardia
Chlamydia
Displaces other drugs from albumin (e.g. Warfarin)
SULFONAMIDES
Sulfamethoxazole (SMX)
Sulfisoxazole
Sulfadiazine
May cause (slow acetylators)... Hypersensitivity reactions Photosensitivity Hemolysis in G6PD deficiency Tubulointerstitial nephritis Kernicterus in infants
Resistance by…
Altered dihydropteroate synthase
Decreased uptake
Increased PABA (precursor) synthesis
Leprosy
DAPSONE
Combine with Rifampin
May cause…
Hemolysis in G6PD deficiency
Methemoglobinemia
Mechanism of Trimethoprim.
Inhibits folate synthesis by inhibiting Dihydrofolate Reductase and thus THF production
Note - Sulfamethoxazole inhibits an earlier enzyme (dihydropteroate synthetase)
UTI (E. coli, Klebsiella, Proteus) Salmonella Shigella Pneumocystis Pneumocystis prophylaxis (CD4 < 200) Toxoplasmosis prophylaxis (CD4 < 100) Nocardia ("SNAP")
TRIMETHOPRIM-SULFAMETHOXAZOLE
May cause... Megaloblastic anemia (folate deficiency) Leukopenia (folate deficiency) Granulocytopenia (folate deficiency) Teratogen (neural tube defects) Hyperkalemia
Mechanism of Fluoroquinolones.
Inhibits DNA replication by inhibition of topoisomerase II (DNA gyrase) and topoisomerase IV.
Gram- rods (GU/GI)
Pseudomonas
Neisseria
Note - Do not take with milk (Ca), antacids (Ca, Mg) or Fe as divalent cations inhibit gut absorption
FLUOROQUINOLONES
Ciprofloxacin
Levofloxacin (Respiratory)
May cause... Myalgia Tendonitis/tendon rupture (>60 y/o, with prednisone) Cartilage damage (children, pregnant/nursing mothers) Prolonged QT Skin rash Headache and dizziness GI upset
Resistance by…
Mutation in DNA gyrase or efflux pumps
Mechanism of Daptomycin.
Lipopeptide disrupts cell membrane of Gram+ cocci.
S. aureus (MRSA) cellulitis, bacteremia, endocarditis
VRE
Note - Cannot be used in pneumonia due to surfactant inactivation
DAPTOMYCIN
May cause…
Myopathy
Rhabdomyolysis
Mechanism of Metronidazole.
Forms toxic free radical metabolites which damage DNA.
Anaerobic infections below the diaphragm:
Clostridium difficile
Bacteroides
("GET Going on the METRO") Giardia Entamoeba Trichomonas Gardnerella vaginalis
Triple therapy for H. pylori
METRONIDAZOLE
May cause…
Disulfiram-like reaction
Metallic taste
Headache
Mechanism of Rifamycins.
Inhibits DNA-dependent RNA polymerase.
RIPE drug
Delay resistance to Dapsone when used for leprosy
Meningococcal prophylaxis
HIB chemoprophylaxis for close contacts
RIFAMYCINS
Rifampin (increased cytochrome P-450 - avoid in HIV)
Rifabutin (combine with Dapsone for leprosy)
May cause…
Orange body fluids
Resistance by…
Monotherapy rapidly leads to reduced binding to RNA polymerase
Mechanism of Isoniazid
Decreased synthesis of mycolic acids in mycobacterial cell wall - Requires activation by catalase-peroxidase (KatG)
RIPE drug
Only agent used as solo prophylaxis against TB
Monotherapy for latent TB
Given with Pyridoxine (vit B6)
ISONIAZID
May cause…
Hepatotoxicity (slow acetylators)
Vit B6 deficiency
Resistance by…
Underexpression of KatG
RIPE drug working in host phagolysosomes.
PYRAZINAMIDE
May cause…
Hepatotoxicity
Hyperuricemia
RIPE drug - Decreases carbohydrate polymerization (cell wall) by blocking arabinosyltransferase
ETHAMBUTOL
May cause... Optic neuropathy (R-G color blindness)
Second line TB drug interfering with 30S component of ribosome.
STREPTOMYCIN
May cause... Tinnitus Vertigo Ataxia Nephrotoxicity
Prophylaxis for patients at high risk of endocarditis.
Amoxicillin
Prophylaxis for history of recurrent UTIs.
TMP-SMX
Prophylaxis following exposure to meningococcal infection.
Ceftriaxone
Ciprofloxacin
Rifampin
Prophylaxis for…
Pregnant women with GBS
Strep pharyngitis with prior rheumatic fever
Exposure to syphilis
Penicillin G
Treatment for multidrug resistant Pseudomonas or Acinetobacter.
Polymyxins B and E (colistin)
Serious systemic mycoses (intrathecally for meningitis)... Aspergillosis Histoplasma Blastomyces Coccidioides Cryptococcus Candida Mucor
AMPHOTERICIN B
Binds ergosterol (unique to fungi) forming membrane pores that allow leakage of electrolytes through cell wall
Supplement K and Mg because of altered renal tubule permeability
May cause... Fever/chills (shake and bake) Hypotension Nephrotoxicity (hydrate) Electrolyte abnormalities Anemia (low EPO) IV phlebitis
Rinse for oral candidiasis
Topical for diaper or vaginal candidiasis
NYSTATIN
Same mechanism as Amphotericin B - too toxic to be used systemically
Systemic fungal infections
Cryptococcal meningitis with AmphoB
FLUCYTOSINE
Inhibits DNA and RNA biosynthesis by conversion to 5-fluorouracil by cytosine deaminase
May cause…
Bone marrow suppression
Mechanism and side effects of Azoles.
Inhibit fungal Ergosterol synthesis via inhibition of cytochrome P-450 - Converts Lanosterol to Ergosterol
May cause…
Testosterone synthesis inhibition (i.e. Ketoconazole)
Liver dysfunction
Chronic suppression of cryptococcal meningitis in AIDS
Candidal infections
Fluconazole
Blastomyces
Coccidioides
Histoplasma
Itraconazole
Topical fungal infections
Clotrimazole
Miconazole
Dermatophytoses (i.e. onychomycosis)
TERBINAFINE
Inhibits fungal enzyme Squalene Epoxidase - Inhibiting Ergosterol synthesis
May cause... Hepatotoxicity Taste disturbance GI upset Headaches
Mechanism of Echinocandins.
Inhibit cell wall synthesis by inhibiting synthesis of B-glucan.
Invasive aspergillosis
Candida
ECHINOCANDINS
Caspofungin
Anidulafungin
Micafungin
May cause…
Flushing (histamine release)
GI upset
Oral treatment of superficial infections especially dermatophytes (tinea, ringworm).
GRISEOFULVIN
Interferes with microtubule function disrupting mitosis - deposits in keratin-containing tissues
May cause... Teratogenic Carcinogenic Confusion Headaches
Mechanism and side effects of scabies and lice (Pediculus, Pthirus) treatment.
(“PML NAGs you”)
Permethrin - Na channel blocker (neurotoxicity)
Malathion - AchE
Lindane - GABA blockade (neurotoxicity)
Treatment of plasmodial species other than P. falciparum.
CHLOROQUINE
Blocks detoxification of heme into hemozoin - heme accumulates and is toxic to plasmodium
Resistance in P. falciparum due to membrane pump that decreases intracellular concentration
May cause…
Retinopathy
Pruritus
Treatment of P. falciparum.
Mefloquine
Atovaquone/Proguanil
Artemether/Lumefantrine
Treatment of life-threatening malaria.
Quinidine
Artesunate
Treatment and prevention of Influenza A/B.
OSELTAMIVIR, ZANAMIVIR
Inhibits influenza neuraminidase - Impaired release of viral progeny
Mechanism and adverse effects of -cyclovirs
Includes…
Acyclovir
Valacyclovir
Famciclovir
Guanosine nucleoside analogs that are monophosphorylated by HSV/VZV Thymidine Kinase leading to DNA chain termination - Not phosphorylated in uninfected cells and so few adverse effects
May cause…
Obstructive crystalline nephropathy/ARF (hydration)
Resistance by…
Mutated viral thymidine kinase
CMV in immunocompromised patients.
GANCICLOVIR
5’-monophosphate nucleoside formed by CMV viral kinase - Preferentially inhibits viral DNA polymerase
May cause…
Bone marrow suppression (leukopenia, neutropenia, thrombocytopenia)
Renal toxicity
Resistance by…
Mutated viral kinase
Ganciclovir-resistant CMV
Acyclovir-resistant HSV
Note - Pyrophosphate analog
FOSCARNET
Does not require viral kinase
May cause... Nephrotoxicity Hypocalcemia (calcium chelator) Hypomagnesemia Seizures
Resistance by…
Mutated DNA polymerase
Ganciclovir-resistant CMV retinitis
Acyclovir-resistant HSV
Note - Nucleotide analog
CIDOFOVIR
Does not require viral kinase
May cause…
Nephrotoxicity (given with Probenecid and IV NaCl)
Ideal regimen for HAART.
2 NRTIs + 1 integrase inhibitor
Mechanism and adverse effects of NRTIs
Includes... Tenofovir ZiDOVudine LAMivudine ABACAvir DIDanosine EMtricitabine
Competitively inhibit nucleotide binding to reverse transcriptase and terminate chain (lack 3’ OH) - Only Tenofovir (nucleotide) does not need to be phosphorylated
May cause... Bone marrow suppression (give G-CSF) Type IV hypersensitivity with HLA-B57:01 (Abacavir) Lipodystrophy Pancreatitis (Didanosine) Lactic acidosis (not Tenofovir)
NRTI for general prophylaxis and during pregnancy.
Zidovudine
Adverse effects of NNRTIs
Includes…
EfaVIRenz
NeVIRapine
DelaVIRdine
Bind at different site than NRTIs - do not require phosphorylation
May cause... SJS-TEN Hepatotoxicity Vivid dreams (Efavirenz) Teratogen (Efavirenz, Delavirdine)
Mechanism of Protease Inhibitors (-NAVIR).
Prevent maturation of new viruses by preventing cleaving of polypeptide products into functional parts
Protease inhibitor which can boost other drug concentrations by inhibiting cytochrome P-450.
RITONAVIR
Alternatively - Rifampin contraindicated with PIs due to induction of P-450
May cause... Hyperglycemia Lipodystrophy (Cushing-like) GI intolerance Nephropathy Hematuria (Indinavir)
Mechanism of integrase inhibitors (-Gravir).
Inhibits HIV genome integration into host cell - Prevent mRNA transcription by RNA Pol III
May cause…
Elevated CK
Mechanism of fusion inhibitors (EnFUvirtide, Maraviroc).
Maraviroc binds CCR5 on surface of T cells/monocytes inhibiting interaction with gp120
Enfuvirtide binds gp41 inhibiting viral entry
May cause…
Skin reaction at injection site
Chronic HBV, HCV
Kaposi sarcoma
Hairy cell leukemia
Condyloma cuminatum
INF-A
IFN-b used in MS, and IFN-y used in CGD
May cause... Flu-like symptoms Depression Neutropenia Myopathy
Treats HCV by inhibiting synthesis of guanine nucleotides by competitively inhibiting inosine monophosphate dehydrogenase.
RIBAVIRIN
May cause…
Hemolytic anemia
Severe teratogen
Treats HCV by inhibiting RNA-dependent RNA polymerase acting as a chain terminator.
SOFOSBUVIR
Not monotherapy - use with Ribavirin or Peginterferon alfa
May cause…
Fatigue
Headaches
Nausea
Treats HCV by inhibiting protease preventing viral replication.
SIMEPREVIR
Not monotherapy - use with Ledipasvir (NS5A inhibitor)
May cause…
Photosensitivity
Rash
Mechanism of action of... Alcohol Chlorhexidine Hydrogen Peroxide Iodide
Cell membrane disruption, Protein denaturation
Cell membrane disruption, Cytoplasm coagulation
Free radical production (sporicidal)
Halogenation of proteins/nucleic acids (sporicidal)
Antibiotics to avoid in pregnancy.
“SAFe Children Take Really Good Care”
Sulfonamides (kernicterus, neural tube) Aminoglycosides (ototoxicity) Fluoroquinolones (cartilage damage) Clarithromycin (embryotoxic) Tetracycline (discolored teeth, inhibition of bone growth) Ribavirin (teratogen) Griseofulvin (teratogen) Chloramphenicol (gray baby syndrome)
Bactericidal antibiotics
“Very Finely Proficient At Cell Murder”
Vancomycin Fluoroquinolones Penicillin Aminoglycosides Cephalosporins Metronidazole
Also…
TMP-SMX
Relationship of Km and Vmax in Michaelis-Menten plot.
Km = [S] at 1/2Vmax
Km = Inversely related to affinity of the enzyme for its substrate (i.e less substrate required to reach 1/2Vmax)
Vmax = directly proportional to enzyme concentration
Km, Vmax, and slope in Lineweaver-Burk plot.
Slope = Km/Vmax 1/Vmax = y-intercept -1/Km = x-intercept
Noncompetitive inhibitors change y-intercept
Competitive inhibitors change x-intercept
Effect of reversible competitive antagonists
Resembles substrate
Binds active site
Overcome by increasing [S]…
Vmax
Km/EC50
Pharmacodynamics
Unchanged
Increased
Decreased potency
E.g. Flumazenil
Effect of irreversible competitive antagonists
Resembles substrate
Binds active site
Not overcome by increasing [S]…
Vmax
Km/EC50
Pharmacodynamics
Decreased
Unchanged
Decreased efficacy
Effect of noncompetitive antagonists
Does not resemble substrate
Does not bind active site
Not overcome by increasing [S]…
Vmax
Km/EC50
Pharmacodynamics
Decreased
Unchanged
Decreased efficacy
E.g. Phenoxybenzamine
Volume of distribution (Vd).
Amount in body/Amount in plasma
Low = 3-5 L (plasma) Medium = 15 L (interstitial) High = 40 L (intracellular)
Effect of liver and kidney disease on Vd (decreased protein binding).
Increased Vd
Vd of large/charged molecules and plasma bound proteins.
Low (blood)
Vd of small hydrophilic molecules.
Medium (CSF)
Vd of small lipophilic molecules, especially if bound to tissue protein.
Large (all tissues including fat)
Clearance (CL).
Rate of elimination/Plasma concentration
OR
Vd x Ke (elimination constant) - increased Vd means more volume has to be cleared per same unit time to excrete the same amount of drug
Half-life for first-order kinetics drug.
(0.7 x Vd)/CL
4-5 half-lives to reach steady state (independent of loading/maintenance dosing)
Loading dose.
(Cp x Vd)/F
Cp = target plasma concentration at steady state F = bioavailability or (AUC PO x IV dose)/(AUC IV x PO dose)
Unchanged in renal/liver disease
Maintenance dose.
(Cp x CL x T)/F
T = dosage interval if not administered continuously
Decreased in renal/liver disease
Note - CL and T should match in units (minutes or hours)
Type of interaction describing required presence of cortisol for full effect of catecholamine response.
Permissive interaction
Acute decrease in response to a drug after initial/repeated administration (MDMA, LSD).
Tachyphylactic
Difference between additive and synergistic interactions.
In additive the total effect is equal to the sum of the individual effects (e.g. APAP, ASA), while in synergistic the total effect is only higher than each individual effect (e.g. Clopidogrel, ASA).
Rate of elimination is constant regardless of Cp (plasma concentration) - constant amount of drug is eliminated per unit time so that Cp decreases linearly with time.
ZERO-ORDER ELIMINATION
Capacity-limited elimination - Phenytoin, Ethanol, ASA at toxic doses
Half-life is not constant - decreases with decreasing concentration
Rate of elimination is directly proportional to Cp - constant fraction of drug is eliminated per unit time so that Cp decreases exponentially with time.
FIRST-ORDER ELIMINATION
Flow-dependent elimination - most drugs
Half-life is constant
Mechanism of NaHCO3 induced elimination of weak acids (ASA, Phenobarbital, Methotrexate).
Trapped in basic environment - alkalinization of weak acid (protonated HA) makes species charged (A-), trapping it in the urine for elimination
Mechanism of NH4Cl induced elimination of weak bases (Amphetamines).
Trapped in acidic environment - acidification of a weak base (deprotonated B) makes species charged (protonated BH+), trapping it in the urine for elimination
Note - Alternatively some weak bases (TCAs) are treated by NaHCO3 rather than elimination. Alkalinization of a base (protonated BH+) makes species uncharged (deprotonated B), allowing it to move out of the blood and back into fat to be secreted slowly over time
Phase I drug metabolism - lost in geriatric patients.
Redox
Hydrolysis with cytochrome P-450
Slightly polar, often active product
Phase II drug metabolism - maintained in geriatric patients.
Conjugation (Methylation, Glucuronidation, Acetylation, Sulfation)
Very polar, inactive metabolites for renal elimination
Pharmacokinetic measure of efficacy - maximum effect a drug can have.
Vmax - Increased y-value = increased Vmax
Partial agonists have less efficacy than full agonists
Pharmacokinetic measure of potency - amount needed for a given effect.
EC50 - left-shifting = decreased EC50 = increased potency
Effect of partial agonist
Binds active site…
Vmax
Km/EC50
Pharmacodynamics
Decreased
Independent
Decreased efficacy
E.g. Buprenorphine
Therapeutic index.
TD50/ED50
Therapeutic window
TD50 - ED50
Only sympathetic target organs innervated by cholinergic fibers.
Sweat glands (M) Adrenal medulla (Nn - same as autonomic ganglia)
Innervation type and receptor for somatic system.
Cholinergic innervation
Nm receptor
Mechanism of nicotinic Ach receptors.
Ligand-gated Na/K channels
Increased vascular smooth muscle contraction (inc. SBP)
Increased pupillary dilator muscle contraction (mydriasis)
Increased intestinal/bladder sphincter muscle contraction
a1
Decreased adrenergic outflow Decreased insulin release Decreased lipolysis Decreased aqueous humor production Increased platelet aggregation
a2
Autoreceptor - often on presynaptic membrane for feedback inhibition
Increased heart rate
Increased contractility
Increased renin release
Increased lipolysis
b1
Vasodilation (dec. DBP) Bronchodilation Increased insulin release Increased lipolysis Increased aqueous humor production Decreased uterine tone (tocolysis) Decreased ciliary muscle tone
b2
Note - a2 inhibition of insulin release predominates over b2 induced release
Increased lipolysis
Increased thermogenesis in skeletal muscle
b3
Parasympathetic receptor acting in CNS and enteric nervous system
M1
Decreased heart rate
Decreased atrial contractility
M2
Bronchoconstriction
Increased exocrine gland secretion
Increased insulin secretion
Increased gut peristalsis
Increased bladder contraction
Increased pupillary sphincter muscle contraction (miosis)
Increased ciliary muscle contraction (accommodation)
M3
Receptor relaxing renal vascular smooth muscle
D1
Receptor modulating transmitter release (CNS)
D2
Increased nasal and bronchial mucus production Increased vascular permeability Increased contraction of bronchioles Pruritus Pain
H1
Receptor increasing gastric acid secretion in addition to M3
H2
Receptor increasing vascular smooth muscle contraction in addition to a1
V1
Receptor increasing H2O permeability and resorption in collecting tubules of kidneys
V2
G-protein class of all G-protein-linked 2nd messengers - a1, a2, b1, b2, b3, M1, M2, M3, D1, D2, H1, H2, V1, V
(“After QISSeS you get a QIQ out of SIQ Super Qinky Sex”)
a1 = q a2 = i b1 = s b2 = s b3 = s M1 = q M2 = i M3 = q D1 = s D2 = i H1 = q H2 = s V1 = q V2 = s
Mechanism of Gq receptors
Activates Phospholipase C
Converts PIP2 to DAG and IP3
DAG activates Protein Kinase C
IP3 increases Ca influx (smooth muscle contraction)
Mechanism of Gs receptors
Activates Adenylate cyclase Converts ATP to cAMP Activates Protein Kinase A Phosphorylation of Phospholamban Increased Ca influx Increased inotropy
cAMP-dependent Protein Kinase A (PKA) activated
Inhibition of Myosin light chain kinase
Vasodilatation
Mechanism of Gi receptors
Inhibition of Adenylate cyclase
NE/Amphetamine interaction in synaptic cleft
Amphetamines use NET to enter presynaptic terminal
Use VMAT to enter neurosecretory vesicles
Displace NE from vesicles
NE reaches conc. threshold in presynaptic terminal
NET action is reversed and NE is expelled
Mechanism for hypertensive crisis in patients taking MAOi
Tyramine normally degraded by MAO
Excess Tyramine enters presynaptic vesicles
Other neurotransmitters (e.g. NE) displaced
Increased active presynaptic neurotransmitters
Increased diffusion into synaptic cleft
Increased sympathetic stimulation
Mechanism of Reserpine
Inhibits uptake of Dopamine into vesicles (antipsychotic) where conversion to NE takes place (antihypertensive)
Mechanism and use of Bethanechol
Cholinomimetic - Activates bowel and bladder smooth muscle (M3) and is resistant to AChE
Postoperative ileus
Neurogenic ileus
Urinary retention
Mechanism and use of Carbachol
Cholinomimetic direct agonist - Copy of acetylcholine
Glaucoma